NRT6008

NRT6008 is a small molecule drug currently in phase 1 clinical development for the treatment of unresectable locally advanced pancreatic cancer (LAPC). It is being evaluated as an injectable agent, often in combination with systematic chemotherapy. The primary objective of ongoing trials is to assess its safety and preliminary efficacy. While the precise mechanism of action has not been explicitly detailed in public sources, some trial descriptions refer to it as a Yttrium-90 carbon microsphere-based therapy, suggesting it may function as a radiopharmaceutical or diagnostic/therapeutic agent targeting tumor tissue via localized radiation delivery. The drug is being developed by Chengdu New Radiomedicine Technology Co.,Ltd., with involvement from Chongqing Huapont Pharmaceutical Co. Ltd.